Evidence map›Paper›PMID 38267189›Full record

SynthesisThe Lancet. Neurology2024

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.

Marianne Chapleau, Renaud La Joie, Keir Yong, Federica Agosta, Isabel Elaine Allen, Liana Apostolova, John Best, Baayla D C Boon, Sebastian Crutch, Massimo Filippi and 29 more

Erratum issuedOpen access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Lancet. Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Review
  5. Review
  6. Considerations in Alzheimer's Disease in Women.Current neurology and neuroscience reports · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  16. Article
  17. The spectrum of Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025
    Article
  18. Article
  19. Article
  20. Primary age-related tauopathy.Acta neuropathologica · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 9 countries.

Marianne ChapleauMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Renaud La JoieMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Keir YongDepartment of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London, UK.
Federica AgostaVita-Salute, San Raffaele University, Milan, Italy; Neuroimaging Research Unit, Division of Neuroscience, and Neurology Unit, IRCCS San Raffaele Scientific Insitute, Milan, Italy.
Isabel Elaine AllenDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Liana ApostolovaIndiana University School of Medicine, Indianapolis, IN, USA.
John BestMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Baayla D C BoonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Sebastian CrutchDepartment of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London, UK.
Massimo FilippiVita-Salute, San Raffaele University, Milan, Italy; Neuroimaging Research Unit, Division of Neuroscience, and Neurology Unit, IRCCS San Raffaele Scientific Insitute, Milan, Italy.
Giorgio Giulio FumagalliCenter for Mind/Brain Sciences, University of Trento, Rovereto, Italy.
Daniela GalimbertiFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Jonathan Graff-RadfordMayo Clinic, Rochester, MN, USA.
Lea T GrinbergMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA; Department of Pathology, University of California San Francisco, San Francisco, CA, USA; Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil.
David J IrwinPenn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.
Keith A JosephsMayo Clinic, Rochester, MN, USA.
Mario F MendezDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Patricio Chrem MendezMemory Center, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Buenos Aires Argentina.
Raffaella MigliaccioParis Brain Institute (ICM), FrontLab, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France.
Zachary A MillerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Maxime MontembeaultDouglas Research Centre, Department of Psychiatry, McGill University, Montreal, QC, Canada.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Sára NemesIndiana University School of Medicine, Indianapolis, IN, USA.
Victoria PelakDepartments of Neurology and Ophthalmology, Divisions of Neuro-Ophthalmology and Behavioral Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
Daniela PeraniVita-Salute, San Raffaele University, Milan, Italy; Division of Neuroscience, IRCCS San Raffaele, San Raffaele University, Milan, Italy.
Jeffrey PhillipsPenn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.
Yolande PijnenburgAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
Emily RogalskiMesulam Center for Cognitive Neurology & Alzheimer's Disease, Northwestern University, Evanston, IL, USA.
Jonathan M SchottDepartment of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London, UK; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
William SeeleyMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA; Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
A Campbell SullivanGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.
Salvatore SpinaMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Jeremy TannerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.
Jamie WalkerGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA.
Jennifer L WhitwellMayo Clinic, Rochester, MN, USA.
David A WolkAlzheimer's Disease Research Center, University of Pennsylvania, Philadelphia, PA, USA.
Rik OssenkoppeleAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands; Clinical Memory Research Unit, Lund University, Lund, Sweden.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA; Department of Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA. Electronic address: gil.rabinovici@ucsf.edu.
PCA International Work Group
University of California, San Francisco · USMayo Clinic in Arizona · USUniversity of Pennsylvania · USUniversity Memory and Aging Center · USIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleMayo Clinic in Florida · USThe University of Texas Health Science Center at San Antonio · USIndiana University School of MedicineVrije Universiteit Amsterdam · NLAmsterdam Neuroscience · NLFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITFundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · ARInstitute for Neurodegenerative Disorders · USNational Hospital for Neurology and Neurosurgery · GBNorthwestern University · USUniversity College London · GBUniversity of California, Los Angeles · USUniversity of Colorado Denver · USUniversity of Trento · ITAmsterdam University Medical Centers · NL

Funding

Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Carolyn Wei Zhu · 2020 to 2026
$31.0M
Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 1996 to 2020
$28.9M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDRA WEINTRAUB · 2021 to 2026
$26.3M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
NIA NIH HHS K01 AG061277NIA NIH HHS K24 AG053435NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P50 AG005134NIA NIH HHS P50 AG005138NIA NIH HHS R01 AG050603NIA NIH HHS R01 AG054449NIA NIH HHS R01 AG054519NIA NIH HHS R01 AG060477NIA NIH HHS R01 AG073282NIA NIH HHS R01 AG075802NIA NIH HHS R21 AG051987NIA NIH HHS R35 AG072362NIA NIH HHS RF1 AG050967NIA NIH HHS U01 AG057195NIDCD NIH HHS R01 DC014296
6 · The paper itself

Abstract

backgroundPosterior cortical atrophy is a rare syndrome characterised by early, prominent, and progressive impairment in visuoperceptual and visuospatial processing. The disorder has been associated with underlying neuropathological features of Alzheimer's disease, but large-scale biomarker and neuropathological studies are scarce. We aimed to describe demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy in a large international cohort.

methodsWe searched PubMed between database inception and Aug 1, 2021, for all published research studies on posterior cortical atrophy and related terms. We identified research centres from these studies and requested deidentified, individual participant data (published and unpublished) that had been obtained at the first diagnostic visit from the corresponding authors of the studies or heads of the research centres. Inclusion criteria were a clinical diagnosis of posterior cortical atrophy as defined by the local centre and availability of Alzheimer's disease biomarkers (PET or CSF), or a diagnosis made at autopsy. Not all individuals with posterior cortical atrophy fulfilled consensus criteria, being diagnosed using centre-specific procedures or before development of consensus criteria. We obtained demographic, clinical, biofluid, neuroimaging, and neuropathological data. Mean values for continuous variables were combined using the inverse variance meta-analysis method; only research centres with more than one participant for a variable were included. Pooled proportions were calculated for binary variables using a restricted maximum likelihood model. Heterogeneity was quantified using I

findingsWe identified 55 research centres from 1353 papers, with 29 centres responding to our request. An additional seven centres were recruited by advertising via the Alzheimer's Association. We obtained data for 1092 individuals who were evaluated at 36 research centres in 16 countries, the other sites having not responded to our initial invitation to participate to the study. Mean age at symptom onset was 59·4 years (95% CI 58·9-59·8; I

interpretationThese data indicate that posterior cortical atrophy typically presents as a pure, young-onset dementia syndrome that is highly specific for underlying Alzheimer's disease pathology. Further work is needed to understand what drives cognitive vulnerability and progression rates by investigating the contribution of sex, genetics, premorbid cognitive strengths and weaknesses, and brain network integrity.

fundingNone.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAtrophyBiomarkersCohort StudiesDemographyFemaleHumansMaleMiddle AgedAmyloid beta-PeptidesBiomarkers

Identifiers

PMID38267189
PMCPMC11615965
OpenAlexW4391123303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.